MA32257B1 - Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques. - Google Patents

Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.

Info

Publication number
MA32257B1
MA32257B1 MA33292A MA33292A MA32257B1 MA 32257 B1 MA32257 B1 MA 32257B1 MA 33292 A MA33292 A MA 33292A MA 33292 A MA33292 A MA 33292A MA 32257 B1 MA32257 B1 MA 32257B1
Authority
MA
Morocco
Prior art keywords
agonists
beta
adrenergic receptors
pyrrolidines
hydroxymethyl
Prior art date
Application number
MA33292A
Other languages
Arabic (ar)
English (en)
Inventor
Richard Berger
Lehua Chang
Scott D Edmondson
Stephen D Goble
Sookhee Nicole Ha
Nam Fung Kar
Ihor E Kopka
Bing Li
Gregori J Morriello
Chris R Moyes
Dong-Ming Shen
Liping Wang
Cheng Zhu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32257B1 publication Critical patent/MA32257B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (ia), des compositions pharmaceutiques les comprenant, et des procédés d'utilisation de ceux-ci dans le traitement ou la prévention de maladies médiées par l'activation des adrénorécepteurs ß3.
MA33292A 2008-04-04 2010-10-29 Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques. MA32257B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306308P 2008-04-04 2008-04-04
US20604309P 2009-01-27 2009-01-27
PCT/US2009/039249 WO2009124166A1 (fr) 2008-04-04 2009-04-02 Hydroxyméthyl pyrrolidines en tant qu’agonistes des récepteurs adrénergiques bêta 3

Publications (1)

Publication Number Publication Date
MA32257B1 true MA32257B1 (fr) 2011-04-01

Family

ID=40671093

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33292A MA32257B1 (fr) 2008-04-04 2010-10-29 Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.

Country Status (41)

Country Link
US (3) US8399480B2 (fr)
EP (1) EP2276756B9 (fr)
JP (3) JP4783867B2 (fr)
KR (3) KR101288798B1 (fr)
CN (2) CN102391255B (fr)
AR (1) AR072043A1 (fr)
AT (1) ATE535521T1 (fr)
AU (1) AU2009231714B2 (fr)
BR (1) BRPI0909768B1 (fr)
CA (1) CA2719876C (fr)
CL (1) CL2009000815A1 (fr)
CO (1) CO6331440A2 (fr)
CR (2) CR11751A (fr)
CY (1) CY1112552T1 (fr)
DO (2) DOP2010000294A (fr)
EA (1) EA020135B1 (fr)
EC (1) ECSP10010518A (fr)
ES (1) ES2376278T3 (fr)
FI (1) FIC20240046I1 (fr)
FR (1) FR24C1051I2 (fr)
GE (1) GEP20125666B (fr)
HN (1) HN2010002030A (fr)
HR (1) HRP20120129T2 (fr)
IL (1) IL208215A (fr)
MA (1) MA32257B1 (fr)
ME (1) ME01988B (fr)
MX (1) MX2010010929A (fr)
NI (1) NI201000164A (fr)
NL (1) NL301305I2 (fr)
NO (1) NO2024055I1 (fr)
NZ (1) NZ588266A (fr)
PE (1) PE20091825A1 (fr)
PL (1) PL2276756T3 (fr)
PT (1) PT2276756E (fr)
RS (1) RS52175B (fr)
SG (1) SG188883A1 (fr)
SI (1) SI2276756T1 (fr)
SV (1) SV2010003687A (fr)
TW (1) TWI378098B (fr)
WO (2) WO2009124166A1 (fr)
ZA (1) ZA201006720B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891872A (en) 1988-05-09 1990-01-09 Sussman Martin V Apparatus for incrementally drawing fibers
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CA2770475C (fr) * 2009-08-27 2017-06-27 Merck Sharp & Dohme Corp. Nouveaux agonistes de recepteurs adrenergiques beta 3 derives de pyrrolidine
IN2012DN02782A (fr) * 2009-10-07 2015-09-18 Merck Sharp & Dohme
AU2011245499B2 (en) * 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CA2805427A1 (fr) * 2010-07-23 2012-01-26 Merck Sharp & Dohme Corp. NOUVEAUX AGONISTES DU RECEPTEUR ß3-ADRENERGIQUE DERIVES DE LA PYRROLIDINE
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US8642661B2 (en) * 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
GB2484713A (en) 2010-10-21 2012-04-25 Optovate Ltd Illumination apparatus
JP6042433B2 (ja) * 2011-08-11 2016-12-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ １，２，４−トリアゾリル置換されたケトエノール類
JP6063948B2 (ja) * 2011-10-27 2017-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ベータ３アゴニストおよび中間体を製造するプロセス
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
EP2780448B1 (fr) 2011-11-18 2019-09-11 Codexis, Inc. Biocatalystes pour preparer des hydroxy-carbamates
KR20150020160A (ko) 2012-02-09 2015-02-25 앨씨알엑스, 인크. 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
JP2015178458A (ja) * 2012-07-25 2015-10-08 杏林製薬株式会社 ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩
WO2014108449A1 (fr) 2013-01-08 2014-07-17 Atrogi Ab Procédé de criblage, trousse, méthode de traitement et composé destinés à être utilisé dans une méthode de traitement
CN105307655B (zh) * 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． β−３作動薬および中間体の製造方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN103760286A (zh) * 2014-01-14 2014-04-30 北京万全德众医药生物技术有限公司 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
ES2874579T3 (es) 2014-06-11 2021-11-05 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
BR112017015431A2 (pt) * 2015-01-20 2018-01-16 Merck Sharp & Dohme composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
GB201705365D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
GB201705364D0 (en) 2017-04-03 2017-05-17 Optovate Ltd Illumination apparatus
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP4410295A3 (fr) 2017-06-06 2024-10-16 Urovant Sciences GmbH Utilisation de vibegron pour traiter une vessie hyperactive
EP3634488A1 (fr) 2017-06-06 2020-04-15 Urovant Sciences GmbH Administration de vibegron pour le traitement de la vessie hyperactive
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201718307D0 (en) 2017-11-05 2017-12-20 Optovate Ltd Display apparatus
EP3730141A4 (fr) * 2017-12-21 2021-10-13 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique pour la pollakiurie nocturne
GB201800574D0 (en) 2018-01-14 2018-02-28 Optovate Ltd Illumination apparatus
GB201803767D0 (en) 2018-03-09 2018-04-25 Optovate Ltd Illumination apparatus
GB201807747D0 (en) 2018-05-13 2018-06-27 Optovate Ltd Colour micro-LED display apparatus
WO2019224788A1 (fr) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Utilisation de vibegron pour traiter la douleur associée au syndrome du côlon irritable
EP3802551A4 (fr) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
SG11202103662VA (en) * 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
CN109503500A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种2-(2-氧代吡嗪-1(2h)-基)乙酸的合成方法
CN109734712B (zh) * 2019-01-30 2020-10-20 广东东阳光药业有限公司 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
KR20260049872A (ko) 2019-03-18 2026-04-14 유로반트 사이언시즈 게엠베하 과민성 방광을 치료하기 위한 비베그론의 용도
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
TWI912252B (zh) 2019-07-02 2026-01-21 美商瑞爾Ｄ斯帕克有限責任公司 定向顯示設備
EP4018236A4 (fr) 2019-08-23 2023-09-13 RealD Spark, LLC Appareil d'éclairage directionnel et affichage de confidentialité
US11163101B2 (en) 2019-09-11 2021-11-02 Reald Spark, Llc Switchable illumination apparatus and privacy display
CN114730044B (zh) 2019-09-11 2025-03-21 瑞尔D斯帕克有限责任公司 定向照明设备和隐私显示器
JP7548655B2 (ja) 2019-10-03 2024-09-10 リアルディー スパーク エルエルシー 受動光学ナノ構造を備える照明装置
KR102937412B1 (ko) 2019-10-03 2026-03-12 리얼디 스파크, 엘엘씨 수동형 광학 나노구조를 포함하는 조명 장치
EP4107580A4 (fr) 2020-02-20 2024-03-20 RealD Spark, LLC Appareil d'éclairage et d'affichage
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
JP2024501661A (ja) 2020-12-22 2024-01-15 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を治療するためのビベグロンの使用と併用したジゴキシンのモニタリング方法
WO2022175848A1 (fr) 2021-02-16 2022-08-25 Urovant Sciences Gmbh Méthodes de traitement de l'insuffisance cardiaque au moyen de vibegron
WO2022271582A1 (fr) 2021-06-22 2022-12-29 Reald Spark, Llc Appareil d'éclairage
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
MX2024010708A (es) 2022-03-02 2024-09-10 Bonafide Health Llc Composiciones de acido poliglutamico y metodos para usarlas.
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
CN114920771A (zh) * 2022-05-13 2022-08-19 苏州虞美景盛新药开发有限公司 一种用于膀胱过度活动症的口服新药的中间体新合成工艺
US12048712B2 (en) 2022-10-18 2024-07-30 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法
CN117756809A (zh) * 2023-12-21 2024-03-26 苏州莱克施德药业有限公司 (6s)4,6,7,8-四氢-4-氧代吡咯并[1,2-a]嘧啶-6-羧酸甲酯的合成方法
WO2025262600A1 (fr) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Forme cristalline d'hémihydrate de vibégron

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
RU2321401C2 (ru) * 2002-11-07 2008-04-10 Астеллас Фарма Инк. Лекарственное средство против гиперактивного мочевого пузыря, включающее производное анилида уксусной кислоты в качестве активного ингредиента
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

Also Published As

Publication number Publication date
CR11751A (es) 2010-11-22
FR24C1051I2 (fr) 2026-01-16
FIC20240046I1 (fi) 2024-12-16
ATE535521T1 (de) 2011-12-15
PE20091825A1 (es) 2009-12-04
US8399480B2 (en) 2013-03-19
ECSP10010518A (es) 2010-11-30
EP2276756A1 (fr) 2011-01-26
BRPI0909768A2 (pt) 2015-10-06
WO2009124167A1 (fr) 2009-10-08
US20120258963A1 (en) 2012-10-11
CN102056917B (zh) 2014-11-05
CL2009000815A1 (es) 2009-08-21
KR101288798B1 (ko) 2013-07-23
JP2011510023A (ja) 2011-03-31
JP4783867B2 (ja) 2011-09-28
SV2010003687A (es) 2011-03-23
US20090253705A1 (en) 2009-10-08
KR20120104257A (ko) 2012-09-20
IL208215A (en) 2014-04-30
JP4783870B1 (ja) 2011-09-28
CN102391255B (zh) 2014-07-09
CR20120282A (es) 2012-07-03
HRP20120129T2 (hr) 2012-09-30
JP2012020961A (ja) 2012-02-02
BRPI0909768B1 (pt) 2019-01-15
HRP20120129T8 (en) 2012-04-30
FR24C1051I1 (fr) 2025-01-17
EA020135B1 (ru) 2014-08-29
CO6331440A2 (es) 2011-10-20
DOP2010000294A (es) 2010-12-31
AR072043A1 (es) 2010-08-04
CA2719876A1 (fr) 2009-10-08
GEP20125666B (en) 2012-10-10
CA2719876C (fr) 2013-10-01
PT2276756E (pt) 2012-02-03
US20110028481A1 (en) 2011-02-03
CN102391255A (zh) 2012-03-28
AU2009231714A1 (en) 2009-10-08
NI201000164A (es) 2011-06-21
SI2276756T1 (sl) 2012-04-30
EP2276756B9 (fr) 2012-08-15
JP2011201897A (ja) 2011-10-13
US8247415B2 (en) 2012-08-21
KR101331771B1 (ko) 2013-11-22
CN102056917A (zh) 2011-05-11
JP5432846B2 (ja) 2014-03-05
NL301305I2 (nl) 2024-12-30
US8653260B2 (en) 2014-02-18
NZ588266A (en) 2011-11-25
PL2276756T3 (pl) 2012-04-30
WO2009124166A1 (fr) 2009-10-08
CY1112552T1 (el) 2016-02-10
SG188883A1 (en) 2013-04-30
KR20120118086A (ko) 2012-10-25
MX2010010929A (es) 2010-11-12
ZA201006720B (en) 2011-05-25
ME01988B (fr) 2012-08-31
NO2024055I1 (no) 2024-12-12
HN2010002030A (es) 2012-08-13
EA201071169A1 (ru) 2011-04-29
KR20100126860A (ko) 2010-12-02
ES2376278T3 (es) 2012-03-12
TW200944521A (en) 2009-11-01
EP2276756B1 (fr) 2011-11-30
HK1147099A1 (en) 2011-07-29
RS52175B (sr) 2012-08-31
AU2009231714B2 (en) 2011-11-03
EP2276756B8 (fr) 2012-04-11
DOP2013000267A (es) 2014-01-31
HRP20120129T1 (hr) 2012-03-31
IL208215A0 (en) 2010-12-30
TWI378098B (en) 2012-12-01

Similar Documents

Publication Publication Date Title
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA31683B1 (fr) Composes et procedes pour moduler fxr
JO2686B1 (en) Vehicles
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA30221B1 (fr) Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole